A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer

被引：0
|
作者：
De Tursi, M. [1 ]
Carella, C. [1 ]
Ricevuto, E. [1 ]
Gennari, A. [2 ]
Orlandini, C. [2 ]
Frassoldati, A. [3 ]
Conte, P. F. [3 ]
Iacobelli, S. [1 ]
机构：
[1] Univ G DAnnunzio, Chieti, Italy
[2] Univ Aquila, I-67100 Laquila, Italy
[3] Univ Modena, I-41100 Modena, Italy
来源：
BREAST | 2007年 / 16卷
关键词：
D O I：
10.1016/S0960-9776(07)70161-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
  • [21] Multicenter phase I/II study of efficacy, safety, and pharmacokinetics of vinorelbine and trastuzumab as first-line therapy for HER2-overexpressing metastatic breast cancer
    Aogi, Kenjiro
    Toi, Masakazu
    Iwata, Hiroji
    Ito, Yoshinori
    Sano, Muneaki
    Sato, Yasuyuki
    Saeki, Toshiaki
    Takashima, Shigemitsu
    ANNALS OF ONCOLOGY, 2006, 17 : 75 - 76
  • [22] Phase II study of weekly epirubicin and docetaxel as first line chemotherapy in metastatic breast cancer
    Gamucci, Teresa
    D'Ottavio, Anna Maria
    Gareri, Roberta
    Vaccaro, Angela
    Belli, Franca
    Nunziata, Corrado
    Meliffi, Loretta
    Moscetti, Luca
    Barduagni, Mario
    Sperduti, Isabella
    ANNALS OF ONCOLOGY, 2004, 15 : 48 - 49
  • [23] Efficacy of epirubicin and docetaxel in Her-2 overexpressing breast cancer cell lines
    Mader, R. M.
    Bartsch, R.
    Forstner, B.
    Kalipciyan, M.
    Steger, G. G.
    ONKOLOGIE, 2010, 33 : 53 - 53
  • [24] A phase II trial of split, low-dose docetaxel and low-dose capecitabine:: A tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer
    Silva, Orlando
    Lopes, Gilberto
    Morgenzstern, Daniel
    Lobo, Christopher
    Doliny, Philomena
    Santos, Edgardo
    Abdullah, Sakher
    Gautam, Umang
    Reis, Isildinha
    Welsh, Catherine
    Slingerland, Joyce
    Hurley, Judith
    Gluck, Stefan
    CLINICAL BREAST CANCER, 2008, 8 (02) : 162 - 167
  • [25] Lapatinib in the treatment of HER-2 overexpressing breast cancer
    Vrdoljak, E.
    Boban, M.
    Ban, M.
    JOURNAL OF BUON, 2011, 16 (03): : 393 - 399
  • [26] Randomized multicenter phase III study of epirubicin/paclitaxel versus epirubicin/cyclophosphamide in first-line treatment of metastatic breast cancer:: A study of the AGO Breast Cancer Study Group
    Lück, HJ
    Thomssen, C
    Kuhn, W
    Eidtmann, H
    du Bois, A
    Möbus, V
    Untch, M
    Jackisch, C
    Olbricht, S
    Schröder, W
    Richter, B
    Bauknecht, T
    Köhler, C
    Schulz, R
    von Minckwitz, G
    Blohmer, J
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 8 - 8
  • [27] Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study.
    Sato N.
    Sano M.
    Tabei T.
    Asaga T.
    Ando J.
    Fujii H.
    Yamamoto N.
    Kurosumi M.
    Inoue K.
    Kimura M.
    Breast Cancer, 2006, 13 (2) : 166 - 171
  • [28] Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer
    Luck, HJ
    Thomssen, C
    duBois, A
    Lisboa, BW
    Untch, M
    Kuhnle, H
    Janicke, F
    Meerpohl, HG
    Lindner, C
    Kcnecny, G
    Hecker, D
    Diergarten, K
    SEMINARS IN ONCOLOGY, 1997, 24 (01) : S13 - S16
  • [29] Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first line treatment of metastatic breast cancer: Results of a multicenter phase II study
    Riccardi, A
    Brugnatelli, S
    Danova, M
    Giordano, M
    Pugliese, P
    Luchena, G
    Grasso, D
    Trotti, G
    Berte, R
    Pansini, G
    Tinelli, C
    TUMORI, 2006, 92 (01) : 6 - 12
  • [30] Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin:: A phase II study
    Lissoni, P
    Tancini, G
    Paolorossi, F
    Mandalà, M
    Ardizzoia, A
    Malugani, F
    Giani, L
    Barni, S
    JOURNAL OF PINEAL RESEARCH, 1999, 26 (03) : 169 - 173
12345